Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F13%3A33145180" target="_blank" >RIV/61989592:15110/13:33145180 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/s12325-013-0060-1" target="_blank" >http://dx.doi.org/10.1007/s12325-013-0060-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s12325-013-0060-1" target="_blank" >10.1007/s12325-013-0060-1</a>
Alternative languages
Result language
angličtina
Original language name
Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Original language description
Effective treatments for hormone-receptor-positive (HR+) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstratedthat everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population. BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day)plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR+ advanced BC with recurrence/progression during or after NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent centralradiology review. Overall survival, response rate, and clinical benefit rate were secondary endpoints.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Advances in therapy
ISSN
0741-238X
e-ISSN
—
Volume of the periodical
30
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
15
Pages from-to
870-884
UT code for WoS article
—
EID of the result in the Scopus database
—